Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Menzin

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Applied Health Economics and Health Policy|January 11, 2020
Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System StakeholdersMatthew Sussman, Jeffrey C Yu, Joseph Menzin
Expert Review of Pharmacoeconomics & Outcomes Research|June 17, 2009
Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?Joseph Menzin, Lisa M Lines, Jeno Marton
Clinicoeconomics and Outcomes Research : CEOR|June 25, 2014
Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapyJoseph Menzin, Matthew Sussman, Michael Munsell, et al.
Cephalalgia : an International Journal of Headache|August 26, 2018
Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectivesMatthew Sussman, Jennifer Benner, Peter Neumann, et al.
Current Opinion in Otolaryngology & Head and Neck Surgery|April 7, 2007
The economics of squamous cell carcinoma of the head and neckJoseph Menzin, Lisa M Lines, Lauren N Manning
BMC Health Services Research|December 18, 2012
The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspectiveJoseph Menzin, Leigh Ann White, Christine Nichols, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 4, 2002
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemiaKathleen Lang, Joseph Menzin, Craig C Earle, et al.
Patient Preference and Adherence|January 25, 2017
An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drugMichael Munsell, Molly Frean, Joseph Menzin, et al.
Drugs & Aging|August 25, 2004
Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysisJoseph Menzin, Kathleen Lang, Craig C Earle, et al.
BMC Neurology|June 7, 2017
Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugsMichael Munsell, Molly Frean, Joseph Menzin, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Applied Health Economics and Health Policy|January 11, 2020
Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System StakeholdersMatthew Sussman, Jeffrey C Yu, Joseph Menzin
Expert Review of Pharmacoeconomics & Outcomes Research|June 17, 2009
Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?Joseph Menzin, Lisa M Lines, Jeno Marton
Clinicoeconomics and Outcomes Research : CEOR|June 25, 2014
Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapyJoseph Menzin, Matthew Sussman, Michael Munsell, et al.
Cephalalgia : an International Journal of Headache|August 26, 2018
Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectivesMatthew Sussman, Jennifer Benner, Peter Neumann, et al.
Current Opinion in Otolaryngology & Head and Neck Surgery|April 7, 2007
The economics of squamous cell carcinoma of the head and neckJoseph Menzin, Lisa M Lines, Lauren N Manning
BMC Health Services Research|December 18, 2012
The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspectiveJoseph Menzin, Leigh Ann White, Christine Nichols, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 4, 2002
Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemiaKathleen Lang, Joseph Menzin, Craig C Earle, et al.
Patient Preference and Adherence|January 25, 2017
An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drugMichael Munsell, Molly Frean, Joseph Menzin, et al.
Drugs & Aging|August 25, 2004
Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysisJoseph Menzin, Kathleen Lang, Craig C Earle, et al.
BMC Neurology|June 7, 2017
Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugsMichael Munsell, Molly Frean, Joseph Menzin, et al.
Pageof 8